Your trusted partner for clinical trials in Australia

Australia is a globally recognised destination for infectious disease and vaccine research, offering efficient TGA regulatory pathways, a diverse patient population, and a commercially attractive R&D tax incentive that makes it a preferred choice for international sponsors bringing studies to market.

Emeritus has conducted over 150 vaccine studies across our Melbourne and Sydney facilities, with access to large portions of both city populations for patient recruitment. Our experience spans First-in-Human through to Phase III, giving sponsors a single, trusted partner capable of supporting a vaccine program at every stage of its development.

Australia's growing prevalence of obesity and metabolic conditions, combined with its diverse urban populations, makes it an ideal environment for metabolic disease research, with strong patient recruitment potential across both Melbourne and Sydney. 


To learn more about Australia's position as a leading destination for obesity research, download our white paper.

Sexual health research is an increasingly active area of global clinical development, with growing sponsor investment in novel treatments spanning a broad range of indications. Australia's progressive regulatory environment and diverse patient populations make it a strong destination for studies in this space.

Emeritus has established a strong and growing track record in sexual health research, with experienced Principal Investigators who bring deep therapeutic knowledge and meaningful input into protocol design. Our Melbourne and Sydney facilities feature private consultation spaces designed to support patient comfort and confidence, helping to drive the recruitment and retention outcomes that sponsors in this therapy area depend on. It is an area we are actively expanding, and one where we are committed to being the partner of choice for sponsors bringing sexual health studies to market.

Australia's rheumatology research landscape has evolved in recent years, with changes to the PBS altering the treatment pathway for patients with inflammatory conditions and tightening the eligible pool for certain studies. Navigating this environment requires a site with deep local knowledge and established patient networks.

Emeritus is actively engaged across rheumatology research, with specific expertise in Rheumatoid Arthritis, Osteoarthritis and Gout. Our Chief Medical Officer, Professor Paul Bird, is a world-leading rheumatologist who brings unparalleled insight to protocol design and trial execution, ensuring sponsors benefit from clinical expertise at the highest level from the very first conversation.

Cardiovascular disease remains one of Australia's most significant health challenges, affecting millions of Australians and creating a substantial, well-characterised patient population across our Melbourne and Sydney catchments. This prevalence makes Australia a compelling destination for cardiovascular research at every stage of development.

Emeritus brings strong infrastructure and experienced clinical teams to cardiovascular trials, with purpose-built facilities designed to support the operational demands of this therapy area. Our established patient networks across both cities support efficient recruitment, and our solutions-led approach ensures even the most complex cardiovascular protocols are executed with precision and care.

Australia's dermatology research landscape presents both opportunity and complexity. Shifts in the PBS have refined the eligible patient pool for certain inflammatory skin conditions, making site selection and protocol design critical factors in study success. Sponsors who understand this environment are increasingly seeking partners with the local knowledge to navigate it effectively.

Emeritus has been involved in over 50 studies across the dermatology spectrum, with hands-on experience in conditions including Atopic Dermatitis, Psoriasis and Alopecia. With a patient base weighted toward our Melbourne and Sydney locations, we bring strong recruitment capability alongside a track record of working directly with sponsors to adapt protocols for the Australian market, ensuring studies are designed for success from the outset rather than adjusted after the fact.

Neurological and mental health conditions represent one of the most active and rapidly evolving areas of global clinical research, with significant sponsor investment flowing into novel treatments for conditions including depression, anxiety and Alzheimer's disease.

Australia's well-educated and engaged patient populations make it a strong destination for studies in this space.
Emeritus has direct experience across these indications, supporting cutting edge outpatient studies that are advancing new treatment options for patients. Our clinical teams bring the sensitivity and expertise that neurological and mental health research demands, working closely with sponsors to design and execute trials that are both scientifically rigorous and appropriate for an ambulatory patient population.